





Extended Data Figure 3. Clinical Efficacy Evaluation by Histology



a, Waterfall plot of the best tumor change in squamous histology ($n=23$; three patients with squamous NSCLC had no tumor measurements after baseline scans). **b**, Waterfall plot of the best change in target lesion in non-squamous histology ($n=29$; three patients with non-squamous NSCLC had no tumor measurements after baseline scans). **c**, Spider plot illustrating the depth and duration of response from baseline by RECISTv 1.1 in squamous histology ($n=23$). **d**, Spider plot illustrating the depth and duration of response from baseline by RECISTv 1.1 in non-squamous histology ($n=29$). **e**, Kaplan–Meier curve of PFS estimate in all patients eligible for efficacy analysis according to histology ($n=58$). **f**, Kaplan–Meier curve of OS in all patients eligible for efficacy analysis according to histology ($n=58$).